A cancer patient has better things to do than spend hours in an infusion chair. A medicine that safely reduces that burden represents progress, even when its ingredients are familiar. Washington should encourage the research that makes such improvements possible. However, a proposed Medicare rule could make the next investment harder to justify. Federal officials aim to finalize a change to how Medicare groups medicines for price negotiation.
Peter Pitts
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Peter
Contact Peter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack